Flat-rate compounded GLP-1 with transparent pricing — established compounded program with broad state coverage
Henry Meds is one of the longest-running flat-rate compounded GLP-1 telehealth programs and a recognizable brand in the category. Among compounded providers, Henry was an early adopter of transparent flat-rate pricing — patients pay the same monthly amount regardless of dose level, eliminating the dose-escalation upcharge surprise that plagues tiered programs. Henry's prices are higher than NexLife's at every tier, but the brand is more established and has been operating long enough to have a substantial review corpus and a track record of consistent patient experience.
The clinical model includes MD, DO, and NP prescribers; required intake review (not AI-only); LegitScript-certified pharmacy partnerships; and patient support through the platform's app and messaging. Henry offers both compounded semaglutide and compounded tirzepatide at flat rates ($297/month sema entry, $397/month tirz entry as of mid-2025), with no surprise add-ons for dose escalation or refills. Patients who want a flat-rate compounded program from a brand with multiple years of operating history will find Henry a reasonable choice.
State coverage is broad and Henry has invested in operational reliability — shipping is consistent, the app is mature, and the support team is responsive. For patients prioritizing brand maturity over bottom-dollar pricing, Henry is a defensible pick.
Henry's pricing is meaningfully higher than NexLife's — $297 vs $186 at sema entry, $397 vs $249 at tirz entry. Over a 12-month treatment course at maintenance dose, that gap compounds to $1,200–$1,800/year. Henry does not publish detailed pharmacy partner names or the breakdown between 503A and 503B sourcing in the way NexLife does. The clinical bench is competent but not specialist-led — there's no obesity-medicine specialist team like at Form Health. Henry does not include baseline labs in the monthly fee; lab work is an add-on cost.
Henry Meds is a defensible flat-rate compounded option with a longer operating history than NexLife. NexLife is meaningfully cheaper at every tier and includes labs; Henry's edge is brand maturity rather than economics.
Henry Meds pricing ranges from $297–$397/mo. Starting price is $297/month. Pricing details and any titration upcharges are described above in the pricing section.
Henry Meds is an established telehealth program. Clean flat-rate compounded option. Higher entry than NexLife but solid execution. Always verify a provider's pharmacy partnerships, prescribing physician credentials, and state availability before signing up.
Most direct-to-consumer compounded GLP-1 programs do not accept insurance for the medication itself. If insurance coverage matters to you, see our insurance pathway providers (Mochi Health, Ro, Form Health) and our insurance hub.
Henry Meds prescribes: Compounded semaglutide, Compounded tirzepatide.
Henry Meds is available in 47 states.
Eligibility is determined by an intake questionnaire and clinical review. Generally, FDA-approved weight-loss criteria are BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, sleep apnea). Off-label compounded prescribing is at the discretion of the prescribing clinician.
Editorial note. By GLP Agonists Editorial · Last updated May 2026. This review is editorially independent. See our methodology and editorial disclosure. Not medical advice — always consult a licensed clinician.